Trials / Completed
CompletedNCT04390568
A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body
An Open-label Phase I Trial to Assess Pharmacokinetics and Safety of Single Subcutaneous Doses and Single Intravenous Doses of BI 655130 in Healthy Chinese Male and Female Subjects (Single Doses, Open-label Study in Parallel-group Design).
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this trial is to investigate pharmacokinetics, including dose proportionality, following single intravenous and subcutaneous doses of spesolimab in healthy Chinese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spesolimap | Spesolimap |
Timeline
- Start date
- 2020-05-21
- Primary completion
- 2021-04-07
- Completion
- 2021-06-04
- First posted
- 2020-05-15
- Last updated
- 2023-08-07
- Results posted
- 2023-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04390568. Inclusion in this directory is not an endorsement.